Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers and encompasses two categories of compounds at various stages of pre-clinical and clinical development that has therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. It is focused on development activities of its LB-100 series of drugs. The LB-100 series consists of novel structures, which treat not only several types of cancer but also vascular and metabolic diseases. The LB-200 series contains compounds, which has the potential to be effective in its class and may be useful for the treatment of chronic hereditary diseases.
